Amarin Corp. Faces Antitrust Suit Over Generic Drug Delays (1)

Amarin Corp. was hit with federal antitrust claims in New Jersey over its alleged scheme to delay generic versions of the cardiovascular drug Vascepa—its only product—by using exclusive supply agreements to block rivals from accessing the drug’s active pharmaceutical ingredient.

“Amarin’s hoarding” is “contrary to industry practice” and “cannot be justified by any legitimate business reason,” the complaint says. “The only explanation for Amarin’s various supply agreements is that it has been paying API suppliers to not supply to generic competitors.”

The lawsuit was filed late Tuesday in the U.S. District Court for the District of New Jersey by Dr. ...